FDA Approves Not One, But Two Sickle Cell Disease Gene Therapies
The FDA approved gene therapies from Vertex Pharmaceuticals and Bluebird Bio for sickle cell disease. Both treatments, Casgevy and Lyfgenia, use gene therapy to potentially cure the inherited blood disorder and target those aged 12 and older. Sickle Cell Disease is a rare, debilitating, and life-threatening blood disorder with significant unmet need. Healthy red blood…